Search results for "Cancer staging"

showing 10 items of 23 documents

Relationship of curative surgery on natural killer cell activity in colorectal cancer.

1996

Aim of this study has been to evaluate natural killer (NK) activity in patients with colorectal tumors before and after curative surgery.Forty colorectal cancer patients without distant metastases were stratified according to American Joint Committee on Cancer/International Union Against Cancer staging system into three categories: Stage I (n = 12), Stage II (n = 15), and Stage III (n = 13). All of them underwent curative resection, and there were no major postoperative complications. Venous blood samples were obtained preoperatively, at surgical wound closure, and on the 1st, 7th, and 21st postoperative days. Mononuclear cells were isolated over Ficoll-Hypaque (Lymphoprep, Nycomed Pharma A…

Malemedicine.medical_specialtyColorectal cancerGastroenterologyNatural killer cellSurgical oncologyInternal medicineCarcinomaMedicineHumansPostoperative PeriodStage (cooking)Cancer stagingAgedNeoplasm Stagingbusiness.industryGastroenterologyCancerGeneral MedicineMiddle Agedmedicine.diseaseCytotoxicity Tests ImmunologicColorectal surgerySurgeryKiller Cells Naturalmedicine.anatomical_structureCase-Control StudiesFemalebusinessColorectal NeoplasmsDiseases of the colon and rectum
researchProduct

Impact of structured report on the quality of preoperative CT staging of pancreatic ductal adenocarcinoma: assessment of intra- and inter-reader vari…

2019

Purpose: To evaluate whether a structured radiology report improves the completeness of preoperative CT staging of pancreatic ductal adenocarcinoma (PDA) compared to conventional free-text reports. Methods: We retrospectively included 27 patients (mean age, 64 ± 11.1 years) referred for pancreatic preoperative CT scan for staging of PDA between 2015 and 2018 and in whom a diagnosis of pancreatic adenocarcinoma was ultimately confirmed. Four readers independently reported CT scans with both conventional free-text and structured reports. Differences in reported morphologic and vascular features with the two reports were assessed through McNemar Test. Intra-reader and inter-reader were calcula…

Malemedicine.medical_specialtyStructured ReportingLeft gastric arteryUrologyPancreatic Cancer StagingPancreatic Ductal AdenocarcinomaAdenocarcinomaSplenic artery030218 nuclear medicine & medical imagingGastroduodenal artery03 medical and health sciences0302 clinical medicineMcNemar's testComputed Tomographymedicine.arteryStructured reportingmedicineHumansRadiology Nuclear Medicine and imagingSuperior mesenteric veinAgedNeoplasm StagingRetrospective StudiesAged 80 and overRadiological and Ultrasound Technologybusiness.industryGastroenterologyReproducibility of ResultsMiddle Agedmedicine.diseasePancreatic NeoplasmsSplenic vein030220 oncology & carcinogenesisAdenocarcinomaFemaleRadiologyTomography X-Ray ComputedbusinessCarcinoma Pancreatic Ductal
researchProduct

An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer

2018

PURPOSE: The body mass index (BMI) may be associated with an increased incidence and aggressiveness of urological cancers. In this study, we aimed to evaluate the impact of the BMI on survival in patients with T1G3 non-muscle-invasive bladder cancer (NMIBC). METHODS: A total of 1155 T1G3 NMIBC patients from 13 academic institutions were retrospectively reviewed and patients administered adjuvant intravesical Bacillus Calmette-Guérin (BCG) immunotherapy with maintenance were included. Multivariable Cox regression analysis was performed to identify factors predictive of recurrence and progression. RESULTS: After re-TURBT, 288 patients (27.53%) showed residual high-grade NMIBC, while 867 (82.8…

Malemedicine.medical_treatmentPrognosis.030232 urology & nephrologyComorbidityGastroenterologySettore MED/24 - Urologia0302 clinical medicineBladder cancer; Body mass index; Obesity; PrognosisMedicineBody mass indexAged 80 and overHazard ratioBladder cancerCystoscopyMiddle AgedPrognosisTumor BurdenAdministration IntravesicalEditorialTransitional cell carcinomaChemotherapy Adjuvant030220 oncology & carcinogenesisBCG VaccineDisease ProgressionFemalemedicine.medical_specialtyPrognosiUrologyCystectomyDisease-Free SurvivalCystectomy03 medical and health sciencesAdjuvants ImmunologicInternal medicineHumansObesityMortalityAgedNeoplasm StagingProportional Hazards ModelsRetrospective StudiesCancer stagingCarcinoma Transitional CellBladder cancer; Body mass index; Obesity; Prognosis; UrologyScience & TechnologyBladder cancerbusiness.industryProportional hazards modelmedicine.diseaseUrinary Bladder NeoplasmsConcomitantMultivariate AnalysisbusinessBody mass index
researchProduct

Open Radical Nephrectomy: 35 Years of Experience at the “Luciano Giuliani” Urological Department of the University of Genoa

2006

Objective: Radical nephrectomy remains the gold standard for surgically resectable kidney neoplasms > 4 cm and, in selected cases, also in presence of metastatic disease. We reviewed the records of the patients having surgery at the University of Genoa in the last 35 yr. Methods: We have retrospectively assessed all the radical nephrectomies performed between 1970 and 2005. Among tumours of the kidney subjected to surgical treatment during this period, we found 1105 cases of histologically proven renal cell carcinoma (RCC), 965 of which had records available for the study. The number of cases per year, symptoms at diagnosis, surgical strategy, staging of the tumour, and survival were rev…

Nephrologycancer incidencemedicine.medical_treatmentkidney carcinomamorbiditysepsisRenal cell carcinomacancer diagnosiscancer mortalitynephrectomypostoperative complicationMyocardial infarctioncancer survivaldisease free survivalcancer diagnosiadrenalectomy; article; cancer diagnosis; cancer incidence; cancer mortality; cancer size; cancer staging; cancer surgery; cancer survival; disease free survival; heart infarction; human; kidney carcinoma; lung embolism; lymphadenectomy; metastasis; morbidity; nephrectomy; partial nephrectomy; postoperative complication; priority journal; sepsis; spleen injury; splenectomy; surgical technique; thrombectomyRadical nephrectomyIncidence (epidemiology)articleadrenalectomyRenal cell carcinomaNephrectomypriority journalthrombectomysepsicancer surgerylung embolismmedicine.medical_specialtypartial nephrectomyUrologyheart infarctionsurgical techniquesplenectomyInternal medicinemedicineCarcinomametastasishumanbusiness.industrycancer stagingmedicine.diseaseSurgeryspleen injurycancer sizelymphadenectomySurgerymetastasibusinessKidney cancerKidney diseaseEuropean Urology Supplements
researchProduct

Neoadjuvant therapy for breast cancer

2019

Objective: To evaluate the frequency of neoadjuvant therapy (NT) in women with stage I–III breast cancer in Italy and whether it is influenced by biological characteristics, screening history, and geographic area. Methods: Data from the High Resolution Study conducted in 7 Italian cancer registries were used; they are a representative sample of incident cancers in the study period (2009–2013). Included were 3546 women aged <85 years (groups <50, 50–69, 70–64, and 75+) with stage I–III breast cancer at diagnosis who underwent surgery. Women were classified as receiving NT if they received chemotherapy, target therapy, and/or hormone therapy before the first surgical treatment. Logistic…

OncologyAdultCancer Researchmedicine.medical_specialtymedicine.medical_treatmentBreast NeoplasmsSettore MED/42 - Igiene Generale E Applicata03 medical and health sciences0302 clinical medicineBreast cancerBreast cancerInternal medicineCancer screeningmedicineBiomarkers TumorOdds RatioMammographyHumans030212 general & internal medicineneoadjuvant therapyNeoadjuvant therapyTriple-negative breast cancerTumor markerCancer stagingAgedNeoplasm StagingAged 80 and overmedicine.diagnostic_testGeneral MedicineMiddle Agedmedicine.diseaseCombined Modality TherapyCancer registryTreatment OutcomeOncology030220 oncology & carcinogenesisFemalemultidisciplinaryMammography
researchProduct

The importance of extranodal extension in metastatic head and neck squamous cell carcinoma, in the light of the new AJCC cancer staging system

2017

OncologyCancer Researchmedicine.medical_specialtyWeight lossPhysical activity03 medical and health sciencesCognition; Memory; Attention; Weight loss; Obesity; Meta-analysis; Physical activity; Nutrition0302 clinical medicineCognitionMemoryInternal medicineCarcinomaMedicineAttentionObesityNeoplasm StagingCancer stagingNutritionbusiness.industryPhysical activityExtranodal Extensionextranodal extensionPrognosismedicine.diseaseHead and neck squamous-cell carcinomaMeta-analysisOncologyHead and Neck Neoplasms030220 oncology & carcinogenesisCarcinoma Squamous Cell030211 gastroenterology & hepatologyNeoplasm stagingOral Surgerybusiness
researchProduct

Squamous Cell Carcinoma: Clinical and Pathological Features and Associated Risk Factors in an Observational Study of 118 Patients

2015

Background and objective: In the latest edition of its cancer staging manual, the American JointCommittee on Cancer (AJCC) revised the criteria for staging squamous cell carcinoma (SCC) by introducing high-risk tumor features to define tumor stage (T) and help to identify tumors with a higher risk of metastasis. The aim of this study was to investigate the characteristics associated with SCC meeting the high-risk criteria defined by the AJCC for T2 lesions. Patients and method: We performed a case-case observational study in which patients with SCC were included over a period of 18 months. We collected clinical, anthropometric, and tumor data, and analyzed these using PASW Statistics (SPSS)…

OncologyMalemedicine.medical_specialtyHistologyNeoplasms Radiation-InducedSkin NeoplasmsCumulative ExposureSkin PigmentationDermatologyComorbidityPathology and Forensic MedicineMetastasisRisk FactorsInternal medicinemedicineHumansPathologicalCancer stagingAgedNeoplasm StagingGynecologyAged 80 and overAnthropometrybusiness.industrySmokingAge FactorsCancerOdds ratiomedicine.diseaseComorbidityTumor BurdenKeratosis ActinicHead and Neck NeoplasmsSpainCarcinoma Squamous CellObservational studyFemalebusiness
researchProduct

Is free/total PSA predictive of pathological stage and Gleason score in patients with prostate cancer and serum PSAor=10 ng/ml?

2005

<i>Introduction:</i> To evaluate whether percent free prostate-specific antigen (%-fPSA) could be predictive of pathological stage and Gleason score in patients with prostate cancer (PCa) and serum PSA of 10 ng/ml or less. <i>Materials and Methods:</i> In 100 patients with total PSA≤10 ng/ml who underwent radical retropubic prostatectomy as primary treatment of PCa, %-fPSA levels in organ-confined vs. non-organ-confined PCa and in patients with Gleason score ≤/>7 were compared. <i>Results:</i> 32 patients had an organ-confined and 68 a locally advanced PCa. Median %-fPSA level was 15%; Gleasonscore was <7 in 49 patients, equal to 7 in 40 and >7 i…

OncologyMalemedicine.medical_specialtybusiness.industryUrologyUrologyProstatic NeoplasmsMiddle AgedProstate-Specific Antigenurologic and male genital diseasesmedicine.diseaseProstate cancerAntigenInternal medicinemedicineHumansNeoplasm stagingIn patientProstate cancer stagingStage (cooking)businessPathologicalTotal psaAgedNeoplasm StagingUrologia internationalis
researchProduct

Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial

2019

Abstract Background The 8th edition of the American Joint Committee on Cancer (AJCC) staging has introduced prognostic stage based on anatomic stage combined with biologic factors. We aimed to validate the prognostic stage in HER2-positive breast cancer patients enrolled in the ShortHER trial. Methods The ShortHER trial randomized 1253 HER2-positive patients to 9 weeks or 1 year of adjuvant trastuzumab combined with chemotherapy. Patients were classified according to the anatomic and the prognostic stage. Distant disease-free survival (DDFS) was calculated from randomization to distant relapse or death. Results A total of 1244 patients were included. Compared to anatomic stage, the prognost…

OncologySettore MED/06 - Oncologia Medicamedicine.medical_treatmentlcsh:MedicineAntineoplastic Agents Immunological0302 clinical medicineBreast cancerTrastuzumabAntineoplastic Combined Chemotherapy Protocols8th AJCC030212 general & internal medicineStage (cooking)8th AJCC; Breast cancer; HER2-positive; Prognostic stage; TrastuzumabGeneral MedicineMiddle AgedPrognosisImmunologicalLocal030220 oncology & carcinogenesisFemaleResearch Articlemedicine.drugAdultmedicine.medical_specialtyRandomizationSocio-culturaleAntineoplastic AgentsBreast NeoplasmsDisease-Free Survival03 medical and health sciencesBreast cancerInternal medicinePrognostic stagemedicineAdjuvant therapyHumanserbB-2AgedNeoplasm StagingCancer stagingChemotherapybusiness.industrylcsh:RCancerGenes erbB-2Trastuzumabmedicine.diseaseHER2-positive Breast cancer Trastuzumab Prognostic stage 8th AJCCHER2-positiveNeoplasm RecurrenceGenesNeoplasm Recurrence Localbusiness
researchProduct

The New TNM Staging System for Thyroid Cancer and the Risk of Disease Downstaging

2018

In October 2016 the American Joint Committee on Cancer (AJCC) published the 8th edition of the AJCC/TNM cancer staging system and it has been introduced in clinical practice since 1st January 2018. The effect of most of the changes in the new edition was the downstaging of a significant number of patients into lower stages, reflecting their low risk of thyroid cancer-related death. One of the most relevant modification refers to the role of the microscopic extra-thyroidal tumor invasion, which is no longer considered as criterion for the classification of T3 tumors. With the present study we want to assess the impact of the changes of the new staging system and therefore we analyzed or casi…

Oncologymedicine.medical_specialtyEndocrinology Diabetes and MetabolismDownstaging; Staging system; Thyroid cancer; TNM 2018; Tumor invasion; Endocrinology Diabetes and Metabolism030209 endocrinology & metabolismAggressive diseaseDiseaseTNM staging systemlcsh:Diseases of the endocrine glands. Clinical endocrinology03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicinethyroid cancerstaging systemMedicineStaging systemThyroid cancerCancer stagingOriginal Researchlcsh:RC648-665TNM 2018business.industryThyroidCancerdownstagingtumor invasionmedicine.diseaseDiabetes and Metabolismmedicine.anatomical_structure030220 oncology & carcinogenesisbusinessFrontiers in Endocrinology
researchProduct